Protease receptor antagonism to target blood platelet therapies

Clinical Pharmacology and Therapeutics

Volumn 99, Issue 1, 2016, Pages 72-81

  Holinstat, M ^a   Bray, P F ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 BENZYL 1H INDAZOL 3 YL)BENZOIC ACID ETHYL ESTER; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; CYCLOOXYGENASE 1 INHIBITOR; DABIGATRAN; DIPYRIDAMOLE; EDOXABAN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HIRULOG; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; PURINERGIC P2Y RECEPTOR ANTAGONIST; PZ 128; RIVAROXABAN; TICAGRELOR; TIROFIBAN; TRIFLUSAL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORAPAXAR; NEW DRUG; PROTEINASE INHIBITOR; THROMBIN RECEPTOR;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; DIMERIZATION; ENZYME INHIBITION; GENETIC REGULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOSIS; VASCULAR DISEASE; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; DRUG EFFECTS; VASCULAR DISEASES;

BLOOD PLATELETS; DRUGS, INVESTIGATIONAL; HUMANS; MODELS, BIOLOGICAL; PLATELET AGGREGATION INHIBITORS; PROTEASE INHIBITORS; RECEPTORS, THROMBIN; VASCULAR DISEASES;

EID: 84955238917     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.282     Document Type: Article

References (75)

1. Chandler, A.B., et al,. Coronary thrombosis in myocardial infarction. Report of a workshop on the role of coronary thrombosis in the pathogenesis of acute myocardial infarction. Am. J. Cardiol. 34, 823-833 (1974).
2. Fuster, V., Badimon, L., Badimon, J.J., &, Chesebro, J.H., The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N. Engl. J. Med. 326, 242-250 (1992).
3. Lam, J.Y., Latour, J.G., Lesperance, J., &, Waters, D., Platelet aggregation, coronary artery disease progression and future coronary events. Am. J. Cardiol. 73, 333-338 (1994).
4. Vu, T.K.H., Hung, D.T., Wheaton, V.I., &, Coughlin, S.R., Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64 1057-1068 (1991).
5. Coughlin, S.R., Thrombin signalling and protease-activated receptors. Nature 407, 258-264 (2000).
6. Macfarlane, S.R., Seatter, M.J., Kanke, T., Hunter, G.D., &, Plevin, R., Proteinase-activated receptors. Pharmacol. Rev. 53, 245-282 (2001).
7. Ossovskaya, V.S., &, Bunnett, N.W., Protease-activated receptors: Contribution to physiology and disease. Physiol. Rev. 84, 579-621 (2004).
8. Wolff, T., Miller, T., &, Ko, S., Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive services task force. Ann. Intern. Med. 150, 405-410 (2009).
9. Depta, J.P., &, Bhatt, D.L., New approaches to inhibiting platelets and coagulation. Annu. Rev. Pharmacol. Toxicol. 55, 373-397 (2015).
10. Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71-86 (2002).
11. Antithrombotic Trialists C, Baigent, C., et al,. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849-1860 (2009).
12. Gonzalez-Correa, J.A., et al,. Protective effect of triflusal and its main metabolite htb in an in vitro model of anoxia-reoxygenation in rat brain slices: comparison with acetylsalicylic and salicylic acids. Naunyn Schmiedebergs Arch. Pharmacol. 371, 81-88 (2005).
13. De la Cruz, J.P., Pavia, J., Garcia-Arnes, J., &, Sanchez de la Cuesta, F., Effects of triflusal and acetylsalicylic acid on platelet aggregation in whole blood of diabetic patients. Eur. J. Haematol. 40, 232-236 (1988).
14. Hechler, B., Cattaneo, M., &, Gachet C,. The p2 receptors in platelet function. Semin. Thromb. Hemost. 31, 150-161 (2005).
15. Kim, S., &, Kunapuli, S.P., P2y12 receptor in platelet activation. Platelets 22, 56-60 (2011).
16. Cattaneo, M., Platelet p2 receptors: old and new targets for antithrombotic drugs. Expert Rev. Cardiovasc. Ther. 5, 45-55 (2007).
17. Tantry, U.S., et al,. Working Group on On-Treatment Platelet R. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J. Am. Coll. Cardiol. 62, 2261-2273 (2013).
18. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (caprie). Lancet 348, 1329-1339 (1996).
19. Yusuf, S., et al,. Clopidogrel in unstable angina to prevent recurrent events trial I. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. N. Engl. J. Med. 345, 494-502 (2001).
20. Steinhubl, S.R., et al,. Observation CICftRoED. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288, 2411-2420 (2002).
21. Sugidachi, A., Asai, F., Ogawa, T., Inoue, T., &, Koike, H., The in vivo pharmacological profile of cs-747, a novel antiplatelet agent with platelet adp receptor antagonist properties. Br. J. Pharmacol. 129, 1439-1446 (2000).
22. Wiviott, S.D., et al,. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007).
23. Birkeland, K., Parra, D., &, Rosenstein R,. Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor. J. Blood Med. 1, 197-219 (2010).
24. Gurbel, P.A., et al,. Randomized double-blind assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the onset/offset study. Circulation 120, 2577-2585 (2009).
25. Wallentin, L., et al,. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045-1057 (2009).
26. Gresele, P., Momi, S., &, Falcinelli, E., Anti-platelet therapy: phosphodiesterase inhibitors. Br. J. Clin. Pharmacol. 72, 634-646 (2011).
27. Group, E.S., et al,. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (esprit): randomised controlled trial. Lancet 367, 1665-1673 (2006).
28. Sacco, R.L., et al,. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N. Engl. J. Med. 359, 1238-1251 (2008).
29. Angiolillo, D.J., et al,. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur. Heart J. 29, 2202-2211 (2008).
30. Mavrakanas, T.A., &, Chatzizisis, Y.S., Bivalirudin in stable angina and acute coronary syndromes. Pharmacol. Ther. 152, 1-10 (2015).
31. Rothberg, M.B., Celestin, C., Fiore, L.D., Lawler, E., &, Cook J.R., Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann. Intern. Med. 143, 241-250 (2005).
32. Roe, M.T., &, Ohman, E.M., A new era in secondary prevention after acute coronary syndrome. N. Engl. J. Med. 366, 85-87 (2012).
33. Mega, J.L., et al,. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 366, 9-19 (2012).
34. Nystedt, S., Emilsson, K., Wahlestedt, C., &, Sundelin, J., Molecular cloning of a potential proteinase activated receptor. Proc. Natl. Acad. Sci. U. S. A. 91, 9208-9212 (1994).
35. Ishihara, H., et al,. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 386, 502-506 (1997).
36. Xu, W.F., et al,. Cloning and characterization of human protease-activated receptor 4. Proc. Natl. Acad. Sci. U. S. A. 95, 6642-6646 (1998).
37. Zhao, P., Metcalf, M., &, Bunnett, N.W,. Corrigendum: biased signaling of protease-activated receptors. Front. Endocrinol. 5, 228 (2014).
38. Jamieson, G.A., Pathophysiology of platelet thrombin receptors. Thromb. Haemost. 78, 242-246 (1997).
39. Gether, U., &, Kobilka, B.K., G protein-coupled receptors. II. Mechanism of agonist activation. J. Biol. Chem. 273, 17979-17982 (1998).
40. Palczewski, K., et al,. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289, 739-745 (2000).
41. Stitham, J., Stojanovic, A., Ross, L.A., Blount, A.C., Jr., &, Hwa, J., Clusters of transmembrane residues are critical for human prostacyclin receptor activation. Biochemistry 43, 8974-8986 (2004).
42. Abrams, C.S., &, Brass, L.F., Platelet signal transduction. In Hemostasis and Thrombosis (ed., Coleman, R.W., et al.) 617-629 (Lippincott Williams & Wilkins: Philadelphia, PA, 2006).
43. Holinstat, M., et al,. Par4, but not par1, signals human platelet aggregation via ca2+ mobilization and synergistic p2y12 receptor activation. J. Biol. Chem. 281, 26665-26674 (2006).
44. Macfarlane, S.R., Seatter, M.J., Kanke, T., Hunter, G.D., &, Plevin, R., Proteinase-activated receptors. Pharmacol. Rev. 53, 245-282 (2001).
45. Covic, L., Gresser, A.L., &, Kuliopulos, A., Biphasic kinetics of activation and signaling for par1 and par4 thrombin receptors in platelets. Biochemistry 39, 5458-5467 (2000).
46. Cho, J.R., Rollini, F., Franchi, F., Ferrante, E., &, Angiolillo, D.J., Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar. Vasc. Health Risk Manag. 10, 177-188 (2014).
47. Becker, R.C., et al,. Safety and tolerability of sch 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 373, 919-928 (2009).
48. Tricoci, P., et al,. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N. Engl. J. Med. 366, 20-33 (2012).
49. Morrow, D.A., et al,. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366, 1404-1413 (2012).
50. Covic, L., Gresser, A.L., Talavera, J., Swift, S., &, Kuliopulos, A., Activation and inhibition of g protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc. Natl. Acad. Sci. U. S. A. 99, 643-648 (2002).
51. Covic, L., Misra, M., Badar, J., Singh, C., &, Kuliopulos, A., Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat. Med. 8, 1161-1165 (2002).
52. Leger, A.J., Covic, L., &, Kuliopulos, A., Protease-activated receptors in cardiovascular diseases. Circulation 114, 1070-1077 (2006).
53. Aisiku, O., et al,. Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar. Blood 125, 1976-1985 (2015).
54. Wu, C.C., et al,. Selective inhibition of protease-activated receptor 4-dependent platelet activation by yd-3. Thromb. Haemost. 87, 1026-1033 (2002).
55. Wu, C.C., &, Teng, C.M., Comparison of the effects of par1 antagonists, par4 antagonists, and their combinations on thrombin-induced human platelet activation. Eur. J. Pharmacol. 546, 142-147 (2006).
56. Wen, W., et al,. Substituted indoles as selective protease activated receptor 4 (par-4) antagonists: discovery and SAR of ml354. Bioorg. Med. Chem. Lett. 24, 4708-4713 (2014).
57. Sevigny, L.M., et al,. Protease-activated receptor-2 modulates protease-activated receptor-1-driven neointimal hyperplasia. Arterioscler. Thromb. Vasc. Biol. 31, e100-106 (2011).
58. Uusitalo-Jarvinen, H., et al,. Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arterioscler. Thromb. Vasc. Biol. 27, 1456-1462 (2007).
59. Leger, A.J., et al,. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 113, 1244-1254 (2006).
60. Lin, H., Liu, A.P., Smith, T.H., &, Trejo, J., Cofactoring and dimerization of proteinase-activated receptors. Pharmacol. Rev. 65, 1198-1213 (2013).
61. Arachiche, A., Mumaw, M.M., de la Fuente, M., &, Nieman, M.T., Protease-activated receptor 1 (par1) and par4 heterodimers are required for par1-enhanced cleavage of par4 by alpha-thrombin. J. Biol. Chem. 288, 32553-32562 (2013).
62. de la Fuente, M., Noble, D.N., Verma, S., &, Nieman, M.T., Mapping human protease-activated receptor 4 (par4) homodimer interface to transmembrane helix 4. J. Biol. Chem. 287, 10414-10423 (2012).
63. Khan, A., Li, D., Ibrahim, S., Smyth, E., &, Woulfe, D.S., The physical association of the p2y12 receptor with par4 regulates arrestin-mediated akt activation. Mol. Pharmacol. 86, 1-11 (2014).
64. Pleis, J.R., &, Lethbridge-Cejku, M., Summary health statistics for U.S. adults: national health interview survey, 2006. Vital Health Stat. 10, 1-153 (2007).
65. Thomas, K.L., Honeycutt, E., Shaw, L.K., &, Peterson, E.D., Racial differences in long-term survival among patients with coronary artery disease. Am. Heart J. 160, 744-751 (2010).
66. Berry, J.D., et al,. Lifetime risks of cardiovascular disease. N. Engl. J. Med. 366, 321-329 (2012).
67. Eagle, K.A., et al,. Identifying patients at high risk of a cardiovascular event in the near future: current status and future directions: report of a national heart, lung, and blood institute working group. Circulation 121, 1447-1454 (2010).
68. Bray, P.F., et al,. Heritability of platelet function in families with premature coronary artery disease. J. Thromb. Haemost. 5, 1617-1623 (2007).
69. Edelstein, L.C., Racial differences in human platelet par4 reactivity reflect expression of pctp and mir-376c. Nat. Med. 19, 1609-1616 (2013).
70. Edelstein, L.C., et al,. Common variants in the human platelet par4 thrombin receptor alter platelet function and differ by race. Blood 124, 3450-3458 (2014).
71. Tourdot, B.E., et al,. Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and gq signaling axis. Arterioscler. Thromb. Vasc. Biol. 34, 2644-2650 (2014).
72. Ungerer, M., et al,. Novel antiplatelet drug revacept (dimeric glycoprotein vi-fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 123, 1891-1899 (2011).
73. Agarwal, A., et al,. Targeting a metalloprotease-par1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol. Cancer Ther. 7, 2746-2757 (2008).
74. Yang, E., et al,. Blockade of par1 signaling with cell-penetrating pepducins inhibits akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res. 69, 6223-6231 (2009).
75. Cisowski, J., et al,. Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer. Am. J. Pathol. 179, 513-523 (2011).